TACC2 and glioblastoma: 67 However, these alterations did not produce functional proteins due to a disruption in the FGFR2 kinase domain and are thus unlikely to contribute to oncogenic activity.67 Intriguingly, a recent case report has identified the first case of FGFR2 amplification with a novel FGFR2-TACC2 fusion protein in a glioblastoma patient with an aggressive IDH-mutant tumour.68 Since FGFR alterations have not been previously shown to occur in IDH-mutant glioblastomas, this curious phenotype warrants further investigation for its role in glioblastoma and potential targetability.